Topical Salbutamol Cutaneous Gel Is Safe in a Double-Blind, Placebo-Controlled, Randomized Trial of Scarring from Sutured Wound Margins on the Arms of Healthy Human Volunteers

There are no clinically significant safety signals after the cutaneous administration of salbutamol gel (0.2-10 mM) in humans either local to the site of injury and drug administration or arising from systemic exposure to salbutamol, but the extent of salbutamol absorption decreases as the wound heals, confirming that re-epithelialization of the wound limits the potential for systemic absorption. This trial was prospectively registered with the Medicines and Healthcare products Regulatory Agency with the European Union Drug Regulating Authorities Clinical Trials (EudraCT number: 2017-003118-15).